|
|
標簽模塊
采用生物合成，經FPLC純化，我們可為客戶提供不同長度、不同來源的microRNA mimics，模擬細胞中成熟miRNA的高水平表達，供客戶對miRNA的生物進程及其對體內細胞的調控進行深入研究。 測試方法
用lipofectamine 2000將重組tRNA/miR-34a與化學合成的miR-34a mimics轉染入A549細胞內，用MTT法檢測A549細胞活力；Western blot法檢測miR-34a對靶蛋白表達的抑制。 圖1. tRNA/miR-34a顯著抑制腫瘤生長 圖2. 比較重組tRNA/miR-34a與miR-34a mimics對腫瘤細胞生長抑制及調節靶蛋白表達的功能 1) Ho PY, Duan Z, Batra N, Jilek JL, Tu MJ, Qiu JX, Hu Z, Wun T, Lara PN, DeVere White RW, Chen HW, Yu AM, Bioengineered Noncoding RNAs Selectively Change Cellular miRNome Profiles for Cancer Therapy, J Pharmacol Exp Ther. 2018 Jun;365(3):494-506. 2) Joseph L. Jilek#, Ye Tian#, Ai-Ming Yu*, Effects of MicroRNA-34a on the Pharmacokinetics of Cytochrome P450 Probe Drugs in Mice, Drug Metab Dispos, 2017, 45 (5): 512-522. 3) Zhao Y, Tu MJ, Wang WP, Qiu JX, Yu AX, Yu AM. Genetically engineered miR-34a prodrug suppresses orthotopic osteosarcoma tumor growth via the induction of apoptosis and cell cycle arrest. Sci Rep.2016, 6:26611. 4) Zhijian Duan and Ai-Ming Yu, Bioengineered non-coding RNA agent (BERA) in action, Bioengineered. 2016 Nov-Dec; 7(6): 411–417. 5) Wang WP, Ho PY, Li MM, Chen QX, Addepalli B, Tu MJ, Limbach PA, Li MM, Wu WJ, Jilek JL, Qiu JX, Zhang HJ, Li T, Wun T, DeVere White R, Lam KS, Yu AM. Bioengineering novel chimeric microRNA-34a for prodrug cancer therapy: High-yield expression and purification, and structural and functional characterization. J. Pharmacol. Exp. Ther. 2015, 354(2):131-141 . 6) Li MM, Addepalli B, Tu MJ, Chen QX, Wang WP, Limbach PA, LaSalle JM, Zeng S, Huang M, Yu AM. Chimeric miR-1291 biosynthesized efficiently in E. coli is effective to reduce target gene expression in human carcinoma cells and improve chemosensitivity. Drug Metab Dispos. 2015, 43(7): 1129-1136. 7) Chen QX, Wang WP, Zeng S, Uroyama S, Yu AM. A general approach to high-yield biosynthesis of chimeric RNAs bearing various types of functional small RNAs for broad applications. Nucleic Acids Res, 2015, 43(7): 3857-3869. 8) Yong Zhao,1,2 Mei-Juan Tu,2 Yi-Feng Yu,1 Wei-Peng Wang,2 Qiu-Xia Chen,2 Jing-Xin Qiu,3 Ai-Xi Yu,1 and Ai-Ming Yu2, Combination therapy with bioengineered miR-34a prodrug and doxorubicin synergistically suppresses osteosarcoma growth, Biochem Pharmacol. 2015 Dec 15; 98(4): 602–613. 9) Li MM, Wang WP, Wu WJ, Huang M, and Yu AM. Rapid production of novel pre-microRNA agent hsa-mir-27b in Escherichia coli using recombinant RNA technology for functional studies in mammalian cells. Drug Metab Dispos.2014, 42(11): 1791-1795. |
